Treatment of stage I testicular germ-cell tumors.
More than a half of patients with testicular cancer are diagnosed with clinical stage I disease. In this setting, definitive cure is the rule. However, there is no consensus on the optimal treatment choice. A literature review (1990-2005) was performed in order to identify the pros and the cons associated with each therapy, as well as their long-term outcomes. Several treatment alternatives yield similar efficacy results. Thus, therapy-related morbidity, economic costs, quality-of-life issues, and patient preferences should be considered. Refinement in the knowledge of predictive factors for relapse and amounting experience with both surveillance and adjuvant chemotherapy have led to consideration of risk-adapted treatment policies as an alternative to more traditional approaches (i.e., prophylactic irradiation for seminomas and retroperitoneal lymph node dissection for non-seminomas). In conclusion, with cure rates approaching 100%, close surveillance for low-risk patients and adjuvant chemotherapy for those at high risk of relapse seems the preferred option for clinical stage I testicular cancer, in both seminoma and non-seminoma cases.
Aparicio
Jorge
J
Department of Medical Oncology, Hospital Universitario La Fe, Valencia, Spain. japariciou@seom.org
Germà
J R
JR
D017024:Chemotherapy, Adjuvant / Q000379:methods; D006801:Humans; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000601:surgery; D008297:Male; D008495:Medical Oncology / Q000379:methods*; D009373:Neoplasms, Germ Cell and Embryonal / Q000628:therapy*; D011379:Prognosis; D018714:Radiotherapy, Adjuvant / Q000379:methods; D012008:Recurrence; D012306:Risk; D018239:Seminoma / Q000628:therapy; D013736:Testicular Neoplasms / Q000628:therapy*; D016896:Treatment Outcome